XML 33 R24.htm IDEA: XBRL DOCUMENT v3.23.2
Stock-Based Compensation Plans
6 Months Ended
Jun. 30, 2023
Share-Based Payment Arrangement, Noncash Expense [Abstract]  
Stock-Based Compensation Plans Stock-Based Compensation Plans
As of June 30, 2023, approximately 1.2 million shares were available for future grants, assuming the maximum number of shares are issued for the performance awards outstanding, approved under the Company Stock Incentive Plans (“the Plans”). Descriptions of the Plans are included in Note (18) “Stock Compensation Plans and Other Employee Benefit Plans” of the 2022 Form 10-K.

Stock-based compensation expense recognized in the Consolidated Statements of Income was $8.1 million in the second quarter of 2023 and $7.0 million in the second quarter of 2022, and $16.4 million and $14.9 million in the six months ended June 30, 2023 and 2022, respectively.

A summary of the Plans’ stock option activity for the six months ended June 30, 2023 and June 30, 2022 is presented below:
Stock OptionsCommon
Shares
Weighted
Average
Strike Price
Remaining
Contractual
Term (1)
Intrinsic
Value (2)
(in thousands)
Outstanding at January 1, 2023
68,093 $41.14 
Granted  
Exercised(54,218)40.87 
Forfeited or canceled  
Outstanding at June 30, 2023
13,875 $42.18 4.5$422 
Exercisable at June 30, 2023
13,875 $42.18 4.5$422 

Stock OptionsCommon
Shares
Weighted
Average
Strike Price
Remaining
Contractual
Term (1)
Intrinsic
Value (2)
(in thousands)
Outstanding at January 1, 2022
193,447 $41.62 
Granted— — 
Exercised(83,507)42.39 
Forfeited or canceled(1,430)40.87 
Outstanding at June 30, 2022
108,510 $41.04 1.2$4,244 
Exercisable at June 30, 2022
108,510 $41.04 1.2$4,244 
(1)Represents the remaining weighted average contractual life in years.
(2)Aggregate intrinsic value represents the total pre-tax intrinsic value (i.e., the difference between the Company’s stock price on the last trading day of the quarter and the option exercise price, multiplied by the number of shares) that would have been received by the option holders if they had exercised their options on the last day of the quarter. Options with exercise prices above the stock price on the last trading day of the quarter are excluded from the calculation of intrinsic value. The intrinsic value will change based on the fair market value of the Company’s stock.
The aggregate intrinsic value of options exercised during the six months ended June 30, 2023 and June 30, 2022, was $2.5 million and $4.7 million, respectively. Cash received from option exercises under the Plans for the six months ended June 30, 2023 and June 30, 2022 was $2.2 million and $3.5 million, respectively.

A summary of the Plans’ restricted share activity for the six months ended June 30, 2023 and June 30, 2022 is presented below:
Six months ended June 30, 2023Six months ended June 30, 2022
Restricted SharesCommon
Shares
Weighted
Average
Grant-Date
Fair Value
Common
Shares
Weighted
Average
Grant-Date
Fair Value
Outstanding at January 1610,155 $73.21 476,813 $61.33 
Granted260,173 88.29 204,043 96.95 
Vested and issued(103,161)64.08 (56,380)64.44 
Forfeited or canceled(7,638)82.82 (9,722)72.87 
Outstanding at June 30
759,529 $79.52 614,754 $72.68 
Vested, but deferred, at June 30
98,247 $53.35 96,400 $52.83 

A summary of the Plans’ performance-based stock award activity, based on the target level of the awards, for the six months ended June 30, 2023 and June 30, 2022 is presented below:
Six months ended June 30, 2023Six months ended June 30, 2022
Performance-based Stock Common
Shares
Weighted
Average
Grant-Date
Fair Value
Common
Shares
Weighted
Average
Grant-Date
Fair Value
Outstanding at January 1545,379 $70.30 557,255 $62.94 
Granted186,313 92.45 160,326 97.16 
Added by performance factor at vesting23,161 63.64 — — 
Vested and issued(178,203)63.64 — — 
Forfeited or canceled(7,909)82.73 (163,803)71.44 
Outstanding at June 30
568,741 $79.20 553,778 $70.34 
Vested, but deferred, at June 30
36,438 $44.99 35,424 $44.04